THERAVECTYS
Theravectys is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, cancers, and other diseases and conditions. Their first clinical studies will be in HIV/AIDS, using their lead product, a therapeutic vaccine, which has shown promising efficacy and safety in non-human primates.
THERAVECTYS
Industry:
Biopharma Biotechnology Health Care
Founded:
2005-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.theravectys.site
Total Employee:
1+
Status:
Active
Contact:
33 1 44 38 93 13
Total Funding:
40.58 M EUR
Technology used in webpage:
Domain Not Resolving Euro Person Schema Gravatar Profiles UNPKG Leaflet OpenStreetMap
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Vaxcyte
Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Current Advisors List
Board_member
Current Employees Featured
Ye Tian Chief Executive Officer @ Theravectys
Chief Executive Officer
2010-01-01
Pierre Charneau Chief Scientific Officer & Founder @ Theravectys
Chief Scientific Officer & Founder
2000-01-01
Jean Chalopin Chairman @ Theravectys
Chairman
Founder
Investors List
Bpifrance
Bpifrance investment in Grant - Theravectys
Tethys BioScience
Tethys BioScience investment in Series D - Theravectys
Guy PAILLAUD
Guy PAILLAUD investment in Series C - Theravectys
Richard HENNESSY
Richard HENNESSY investment in Series C - Theravectys
Philippe ODDO
Philippe ODDO investment in Series C - Theravectys
John PIETERS
John PIETERS investment in Series C - Theravectys
More informations about "Theravectys"
ABOUT US - TheraVectys : Immunize - Treat - Cure
TheraVectys is pioneering the application of novel lentiviral vector technology to address most of unmet and critical medical needs. By creating the only Joint-Laboratory between a private company and the Institut Pasteur in Paris, …See details»
Management Team - TheraVectys : Immunize - Treat
Jean Chalopin is an experienced creative entrepreneur and businessman. As the Executive Chairman of Deltec International Group, a long-standing private bank, he has been instrumental to the negotiation, management, operation and …See details»
Theravectys - Crunchbase Company Profile & Funding
Theravectys is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, …See details»
Theravectys 2025 Company Profile: Valuation, Funding …
Website www.theravectys.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. 25-28 Rue du …See details»
THERAVECTYS Company Profile | PARIS, ILE DE FRANCE, France ...
THERAVECTYS Company Profile | PARIS, ILE DE FRANCE, France | Competitors, Financials & Contacts - Dun & BradstreetSee details»
Theravectys SAS:Company Profile & Technical …
Theravectys is a company that provides Health care, Cancer, Gene delivery and more. Theravectys is headquartered in France Ile-de-France. Theravectys was founded in 2005. …See details»
Theravectys - Funding, Financials, Valuation & Investors
Theravectys develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions. New. Resources. Advanced Search. ... How much funding has this …See details»
THERAVECTYS - VentureRadar
THERAVECTYS, a biotechnology company, has developed a new generation of vaccines based on lentiviral vector technology. Built on the results of fundamental research conducted at the …See details»
THERAVECTYS Company Overview, Contact Details & Competitors …
Feb 8, 2021 Learn more about THERAVECTYS's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today. ...See details»
Theravectys Company Profile - Office Locations, Competitors
Theravectys has 5 employees across 2 locations and $31.68 m in total funding,. See insights on Theravectys including office locations, competitors, revenue, financials, executives, …See details»
Theravectys: an Orphan Drug Designation for Its ... - Labiotech.eu
Feb 22, 2015 THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and …See details»
TECHNOLOGY - TheraVectys : Immunize - Treat - Cure
TheraVectys’ proprietary lentiviral vector technology is continuously optimized to deliver unrivalled capacity to induce strong, efficient and long lasting cellular immune responses and humoral …See details»
TheraVectys - Overview, News & Similar companies - ZoomInfo
Who is TheraVectys. To cure cancers and prevent infectious diseases through therapeutic, prophylactic and personalized vaccination. Lentiviral vectors have the power t o cure and …See details»
Theravectys - Contacts, Employees, Board Members, Advisors
Theravectys has 3 current employee profiles, including Chief Executive Officer Ye Tian. Theravectys has 2 board members and advisors, including Tom McKillop . ContactsSee details»
THV 01 - AdisInsight - Springer
Dec 1, 2017 27 Feb 2019 Theravectys completes a phase I/II trial in HIV infections in Belgium and France (NCT02054286) (EudraCT2011-006260-52) 01 Dec 2017 THV 01 is still in phase …See details»
PIPELINES - TheraVectys : Immunize - Treat - Cure
In the foreseeable future, TheraVectys intends to directly or via collaboration prepare or launch 5 clinical trials. TheraVectys has already started a Phase /IIa clinical trial on: HPV-induced …See details»
OUR MISSION - TheraVectys : Immunize - Treat - Cure
In June 2017, TheraVectys and the Institut Pasteur formed a Joint-Laboratory to build a solid portfolio of potential candidates for clinical development. To support the development of our …See details»
THERAVECTYS Company Information - Funding, Investors, and More
THERAVECTYS. A company developing T-cells vaccines for the treatment and prevention of infectious diseases, virally-induced cancers and cancers . Seedtable Score 76 Startups. 2. …See details»
HPV Induced Cancers by Theravectys for Cervical Cancer: …
Jan 5, 2025 Theravectys is a biotechnology company that specializes in the development of therapeutic vaccines and immunotherapies. The company’s primary focus is on the creation of …See details»
3 more MS-13 gang members arrested in Florida murder cases, …
2 days ago A total of nine suspects with ties to MS-13 have now been arrested in connection with four murder cases in South Florida in 2014 and 2015. U.S. Attorney General Pam Bondi …See details»